Jun 16, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Pevion's Breakthrough Candida Vaccine Demonstrates Safety And Immunogenicity In Phase
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2392198" data-attributes="member: 124445"><p>Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. Vaccination of the first study group has been completed and demonstrated that PEV7 is safe and well-tolerated in all subjects and elicits an immune response even at low doses...<a href="http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/wum9CGwiK1E" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/wum9CGwiK1E/3MvK" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2392198, member: 124445"] Pevion Biotech AG today announced positive preliminary results from a Phase I study of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC). Also known as chronic recurrent thrush, RVVC is a highly debilitating condition, which affects an estimated 3-6% of women worldwide. Vaccination of the first study group has been completed and demonstrated that PEV7 is safe and well-tolerated in all subjects and elicits an immune response even at low doses...[URL="http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/0/da"][IMG]http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/1/da"][IMG]http://feedads.g.doubleclick.net/~a/AMpGK1XRardkj2xCp2dkw0S8tMc/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/wum9CGwiK1E[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/wum9CGwiK1E/3MvK]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top